Gene-Guided chemo cocktail aims to tame tough pancreatic cancer
NCT ID NCT05929885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a three-drug chemotherapy regimen given at lower, continuous doses for people with metastatic pancreatic cancer. The drugs—capecitabine, oxaliplatin, and irinotecan—are dosed based on a patient's genetic profile to reduce side effects. The goal is to see if this approach shrinks tumors or keeps them stable for at least six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine, oxaliplatin, irinotecan
What this could lead to
If successful, this could offer a more tolerable chemotherapy option for people with advanced pancreatic cancer, potentially improving response rates.
What could go wrong
This is a small, early-phase trial (50 people) at a single center, so results may not apply broadly. The chemo still carries risks like fatigue, nausea, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre, Singapore
RECRUITINGSingapore, 168583, Singapore
Contact